LaRochelle, William [MC????]
Dr. William J. LaRochelle, Ph.D. serves as Head of Healthcare & Key Opinion Leader Management at Roche 454 Sequencing Solutions. He is also member of firm’s International Business Team. In addition, he is the Roche 454 global liaison to Genentech, Roche Pharma, Chugai and external key opinion leaders for Roche’s personalized healthcare strategy in cancer genomic medicine.
Dr. LaRochelle joined Roche 454 Sequencing Solutions from its former parent company, CuraGen Corporation, where he directed the Preclinical Drug Development Program. He previously directed the Translational Oncology Program at CuraGen. His group was responsible for using CuraGen’s genomics technologies to identify and validate drug targets within the fully human monoclonal antibody alliance with Amgen Fremont in concert with Seattle Genetic’s antibody drug conjugate technology.
Prior to joining CuraGen, Dr. LaRochelle was a principle investigator at the National Cancer Institute in the Laboratory of Cellular and Molecular Biology for over 13 years.
His academic research was focused on growth factor signal transduction and neutralizing antibodies in cancer and inflammation. He received an American Cancer Society Postdoctoral Fellowship to study oncogene signal transduction at the National Cancer Institute. Following his fellowship, Dr. LaRochelle assumed his appointments as staff fellow, senior staff fellow and finally principal investigator at the National Cancer Institute at the National Institutes of Health (NIH).
He is the author of over 80 peer-review publications and numerous patents, the editor of the Oncogenomics Handbook, and the recipient of multiple Federal Technology Transfer Awards. Dr. LaRochelle earned his degrees from Dartmouth Medical School (Ph.D. – Biochemistry) and Manhattan College (B.S. in Biochemistry).
# – # – # – # – #
I believe that William is a member of the Class of 1982.
McEneney, Mike (MC1953)
[JR: Thanks, Mike. Much appreciated.]
LaRochelle, William [MC1982]
# – # – # – # – #